Efectividad de belimumab en el tratamiento de la nefritis lúpica: análisis de 8 casos / Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases
Med. clín (Ed. impr.)
; 159(7): 344-346, octubre 2022.
Article
in Es
| IBECS
| ID: ibc-212210
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
RESUMEN
Introducción y objetivo:
Belimumab es un anticuerpo monoclonal aprobado para pacientes con lupus eritematoso sistémico (LES), con indicación reciente para nefritis lúpica (NL).El objetivo es analizar la eficacia de belimumab en pacientes con NL.MétodosEstudio transversal, retrospectivo, que incluye pacientes diagnosticados de LES (criterios SLICC/ACR 2012), con nefritis demostrada mediante biopsia, tratados con belimumab. Se recogieron datos serológicos, función renal (creatinina y filtrado glomerular) y sedimento urinario.ResultadosSe incluyen 8 pacientes con edad media de 37,56 (7,03) años, con 15,13 (8,71) años de evolución de la enfermedad y 4,61 (2,64) años desde el inicio de belimumab.La proteinuria se redujo hasta alcanzar valores normales en 6 pacientes, manteniéndose la función renal estable desde el inicio del tratamiento en todos los casos. Se registró una reducción del nivel de anti-DNA y una normalización del complemento en los casos en que estaba reducido. En uno de los pacientes se registró un aumento del título de anti-DNA, manteniéndose el complemento normal. (AU)ABSTRACT
Introduction and objective:
Belimumab is a monoclonal antibody targeting BLyS approved for Systemic Lupus Erythematosus (SLE), with recent indication for lupus nephritis (LN).To analyze effectiveness of Belimumab in LN patients.MethodsRetrospective and cross-sectional study including SLE patients (SLICC/ACR 2012 criteria) with LN demonstrated by kidney biopsy, treated with Belimumab. A clinical history review was made and serological data, kidney function and urine sediment were collected.ResultsEight patients with LN demonstrated by kidney biopsy were included. Median age was 37.56 (7.03) years, with 15.13 (8.71) years since SLE diagnosis was made and 4.61 (2.64) years since onset of belimumab.Proteinuria was reduced to normal values in 6 patients, and renal function was stable from the beginning of treatment in all cases. There was a reduction in the anti-DNA level and normalization of complement in those cases in which it was reduced. One patient presented an increase in anti-DNA titer, with normal complement.ConclusionsIn clinical practice, belimumab can improve LN in terms of serological activity, kidney function and urine sediment. (AU)Key words
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Lupus Nephritis
/
Antibodies, Antinuclear
/
Antibodies, Monoclonal, Humanized
/
Immunosuppressive Agents
/
Lupus Erythematosus, Systemic
/
Antibodies, Monoclonal
Limits:
Humans
Language:
Es
Journal:
Med. clín (Ed. impr.)
Year:
2022
Document type:
Article